One of the downsides of treatments such as Ozempic or Mounjaro is that even though patients wind up losing weight, they also tend to shed muscle mass. Losing too much muscle mass can be a health risk ...

Novo Nordisk , whose global profile has risen along with demand for its Wegovy weight-loss drug, is bolstering operations in ...

Baird Asset Management controlled Chautauqua Capital Management, a boutique investment firm, released the “Baird Chautauqua ...

Novo Nordisk’s stock declined 12% in the past month. Wegovy's sales growth stays under pressure. Read why I'm neutral on NVO ...

Brookstone Capital Management cut its holdings in shares of Novo Nordisk A/S (NYSE:NVO – Free Report) by 1.1% during the 3rd ...

U.S. Sen. Elizabeth Warren has asked the Federal Trade Commission “closely scrutinize” a $16.5 billion deal in which Novo ...

Concerns are rising as Novo Nordisk's $16.5 billion bid to acquire Catalent faces scrutiny from the FTC. Critics argue the ...

Novo Nordisk and Viatris have agreed to resolve a patent dispute related to Novo's blockbuster weight-loss drugs Ozempic and ...

Danish drug maker Novo Nordisk has struck partnerships with 10 Indian artificial intelligence (AI) startups to streamline its ...

The $200B GLP-1 market is set to expand with 16 new obesity drugs launching by 2029, challenging Novo Nordisk and Eli Lilly's dominance while addressing scalability and pricing concerns.

WeightWatchers said on Tuesday it would offer a compounded version of Novo Nordisk's popular obesity drug Wegovy as part of ...

Senate Democrat Elizabeth Warren urges the Federal Trade Commission to closely scrutinize a proposed merger between Novo Nordisk and contract development and manufacturing organization Catalent, ...